Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression

Southern Medical Journal

Volumn 91, Issue 6, 1998, Pages 573-575

  Longmore, Lynn ^a,b   Foley, John P ^a,b   Rozanski, Thomas A ^a,b   Higgins, Betsy ^a,b   Thompson, Ian M ^a,b  

^a Brooke Army Medical Center ^*

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CASE REPORT; DISEASE COURSE; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; HUMAN; MALE; METASTASIS; POINT MUTATION; PROSTATE CARCINOMA;

EID: 0031749745     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199806000-00013     Document Type: Article

References (8)

1. Denis L: Role of maximal androgen blockade in advanced prostate cancer. Prostate 1994; 5:17-22
2. Kelly WK, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149:607-609
3. Moul JW, Srivastava S, McLeod DG: Molecular implications of the antiandrogen withdrawal syndrome. Semin Urol 1995; 13:157-163
4. Veldscholte J, Ris-Stalpers C, Kuipper GGJM, et al.: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990; 173:534-540
5. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:1566-1572
6. Figg WD, Sartor O, Cooper MR, et al.: Prostate specific anti-gen decline following the discontinuation of flutamide in patients with D2 prostate cancer. JAMA 1995; 98:412-414
7. Thalmann GN, Sikes RA, Chang SM, et al.: Suramin-induced decrease in prostate specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996; 88:794-801
8. Eisenberger MA, Nelson WG: How much can we rely on the level of prostate specific antigen as an end point for evaluation of clinical trials? a word of caution! (Editorial) J Natl Cancer Inst 1996; 88:779-781